Biotechnology company · MIRM

Mirum Pharmaceuticals
clinical trial
pipeline

Registry checked

Published

Brelovitug is linked to 4 distinct active studies, with 4 Phase 3. Maralixibat is linked to 2 distinct active studies, with 1 Phase 2, 1 Phase 3.

Phase 2 study NCT05050136 in Primary Biliary Cholangitis and PBC lists estimated primary completion in January 2027. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

12active trials
as lead sponsor
  • Phase 10
  • Phase 24
  • Phase 35
  • Phase 41
  • Phase not recorded2

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

31 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Primary completion

Direction uncertain at the recorded date precision

2026-07 (estimated)2026-07-08 (actual)

A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379

NCT07712718 · ClinicalTrials.gov
Recorded by ComplyRx
08 Oct 2026
Registry last updated
07 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000000
2026-10-081110031
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160000000
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290000000
2026-10-300000000
2026-10-310000000
Type totals1110031 distinct

02 / Drugs & programmes

Explore the pipeline

5 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Brelovitug

Canonical investigational asset

4
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Chronic Hepatitis D · Chronic Hepatitis D Infection
Next primary completion
30 June 2027 · estimated
Open drug

Maralixibat

LIVMARLI

2
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 21
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) · Intrahepatic Cholestasis of Pregnancy
Next primary completion
Not reported
Open drug

Volixibat

Canonical investigational asset

2
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 10
  • Phase 22
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
PBC · Primary Biliary Cholangitis · Primary Sclerosing Cholangitis
Next primary completion
Jan 2027 · estimated
Open drug

Livmarli (maralixibat)

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 41
  • Phase not recorded0
Studied condition
Alagille Syndrome · Progressive Familial Intrahepatic Cholestasis
Next primary completion
Not reported
Open drug

MRM-3379

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 10
  • Phase 21
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Fragile X Syndrome
Next primary completion
Oct 2027 · estimated
Open drug

10 of 12 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

5 selected programmes · accepted investigational links cover 10 of 12 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Mirum Pharmaceuticals trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
VANTAGE
Volixibat

NCT05050136

Phase 2 · Active, not recruiting

Trial source and qualifications

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

5 candidate observations · 3 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

2 inspected observations omitted. At most three verified observations are shown, not full history.

  • enrollment change · Recorded 2026-08-26 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
  • status flip · Recorded 2026-08-26 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
  • pc date moved · Recorded 2026-08-26 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 22 Sept 2021 · actual
Primary completion: Jan 2027 · estimated
Study completion: Dec 2028 · estimated

2021202220232024202520262027202820292030
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Brelovitug

NCT07200908

Phase 3 · Recruiting

Trial source and qualifications

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

No eligible observations recorded in the inspected period.

    Start: 27 Aug 2025 · actual
    Primary completion: 30 Jun 2027 · estimated
    Study completion: 30 Sept 2029 · estimated

    2021202220232024202520262027202820292030
    Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
    Brelovitug

    NCT07454837

    Phase 3 · Recruiting

    Trial source and qualifications

    Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

    0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    No eligible observations recorded in the inspected period.

      Start: 26 Feb 2026 · actual
      Primary completion: 31 Aug 2027 · estimated
      Study completion: 30 Mar 2029 · estimated

      2021202220232024202520262027202820292030
      Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
      MRM-3379

      NCT07209462

      Phase 2 · Recruiting

      Trial source and qualifications

      Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

      1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      1 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 22 Nov 2025 · actual
        Primary completion: Oct 2027 · estimated
        Study completion: Oct 2027 · estimated

        2021202220232024202520262027202820292030
        OASIS
        Maralixibat

        NCT07823127

        Phase 2 · Not yet recruiting

        Trial source and qualifications

        MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

        0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        No eligible observations recorded in the inspected period.

          Start: 15 Jan 2027 · estimated
          Primary completion: 12 Jan 2029 · estimated
          Study completion: 12 Jan 2029 · estimated

          2021202220232024202520262027202820292030
          A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
          Brelovitug

          NCT06907290

          Phase 3 · Active, not recruiting

          Trial source and qualifications

          A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

          3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          3 inspected observations omitted. At most three verified observations are shown, not full history.

            Start: 25 Mar 2025 · actual
            Primary completion: May 2029 · estimated
            Study completion: Sept 2029 · estimated

            2021202220232024202520262027202820292030

            Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

            6 selected of 6 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 1 actual primary completions, 0 untyped primary completions, 2 past estimates, 0 outside the horizon, 0 contradictory dates.

            04 / Therapeutic focus

            Where the activity is

            4

            active trials in Gastroenterology & Hepatology

            Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

            Active trials by primary therapeutic area

            • Gastroenterology & Hepatology4 trials
            • Infectious Disease3 trials
            • Genetic & Rare Disease1 trials
            • Womens Health1 trials
            • Unmapped3 trials
            • Healthy volunteers0 trials

            Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

            06 / Related companies

            All companies
            T

            Takeda

            Shared indexed programme context · 1 selected asset

            Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

            Sources, scope and methodology

            ClinicalTrials.gov lead-sponsor scope

            Canonical current-owner attribution covers 39 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Mirum Pharmaceuticals, Inc.. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

            ClinicalTrials.gov

            Attribution coverage

            39 distinct registry candidates produced 39 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 39 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

            Indexed enrichment

            35 scoped records have indexed enrichment and 4 do not. Missing enrichment does not remove a trial from cohort counts.

            Scope observation

            The successful attribution check completed at 2026-11-01T01:41:05.785Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot c73c727e21dc9b1282fc2f1861f587dacb1163d10570e2f4db358e4e0281aa1a.

            Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

            Dated canonical-attribution snapshot: 39 mapped lead-sponsored clinical studies across all statuses. 35 have indexed enrichment, 4 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

            Keep following
            what matters.

            Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

            Build your watch

            Choose what to track in the watch builder.